Cycuria Therapeutics, a Graz, Austria-based preclinical stage biotechnology company, received a Public Grant funding of an undisclosed amount.
Grant providers were FFG (Forschungs Förderungs Gesellschaft) and AWS (Austria Wirtschaftsservice Gesellschaft mbH).
The company intends to allocate the amount to expand operations and its development efforts.
Cycuria is developing novel biologics which selectively target both tumour cells and tumour stem cells, while preserving the creation of healthy new blood cells.
Its lead asset, CUR-101, is a novel protein-based targeted therapy for acute myeloid leukaemia (AML). The therapeutic rationale underlying its approach holds significant potential beyond its current focus on AML, potentially extending to other blood cancers as well as hard-to-treat solid cancers.
Cycuria has launched with the formation of an Advisory Board which comprises:
- Dr. Nisit Khandelwal, CEO & Co-Founder
- Prof. Dr. Philipp J. Jost, Inventor & Co-Founder
- John Haurum, M.D., D.Phil.
- Dr. Bertolt Kreft.
- Prof. Dr. Andrew Wei.
- Prof. Dr. Felix Wieland.
- Prof. Dr. Walter Nickel.
The grant funding followed an initial Seed investment from Wieland Capital (WPMB GmbH), a Munich-based family office.
FinSMEs
28/04/2025